You are here


Victoza (Liraglutide) is a long-acting glucagon-like peptide-1 receptor agonist. It was approved by U.S. Food and Drug Administration (FDA) in January 25, 2010. It is manufactured by Danish drug maker, Novo Nordisk and was launched in US on February 2010 and in EU on July 2009.

It acts by binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. It mimics the GLP-1 (glucagon like peptide-1) hormone and controls the blood glucose level when given along with diet and exercise, in adult patients with Type 2 diabetes mellitus.

Serious Alleged Injuries may include
  • Hypoglycemia
  • Kidney failure
  • Severe allergic reaction
  • Pancreatitis
  • Pancreatic cancer
  • Thyroid cancer
FDA warnings:

In April 9, 2012, FDA had given approval for updating the label regarding the superior blood glucose control when compared to Januvia. In June 14, 2011, warning had been issued by the FDA for Victoza about the risks of thyroid cancer and pancreatitis.

In April 2013, warnings and precautions include acute pancreatitis including fatal and non-fatal haemorrhagic and necrotizing pancreatitis.

In March 2015 black box warning, warnings and precautions were modified adding risk of thyroid C- cell tumours including medullary thyroid carcinoma (MTC) and about contraindication in patient with personal or family history of MTC and Multiple Endocrine Neoplasia Syndrome type 2.

Law suits allegation:

Patients are claiming against the manufacturers for the serious side effects which are not warned.

In August 2013 all the federal cases of four drugs Byetta, Januvia, Janumet and Victoza are consolidated into MDL 2452 (Incretin mimetic products liability litigation). Around 800 lawsuits are filed by injured are centralized in U.S. District court for Southern District of California by June 2016.

Evidence to be looked for in potential cases

  • Usage of Victoza in Pharmacy Records
  • Duration of Victoza usage
  • Indications for usage of Victoza in Medical Records
  • Complications and their treatment after Victoza Intake

Medical Record Review and claim validation of Victoza case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.

or Contact Us for a Free Consultation!
Please fill out the details below, or e-mail us at Contact us for more info
Fields marked with '*' are mandatory.
Contact Number with Country code
Any additional information you would like to provide.
This selection is for testing whether you are a human visitor and to prevent automated spam submissions.
All fields are mandatory.